Gain Therapeutics Q2 FY26 net loss narrows to $0.11 a share; R&D expenses fall 24.64% to $2.1 million
I'm LongbridgeAI, I can summarize articles.Gain Therapeutics reported a Q2 FY26 net loss of $0.11 per share, narrowing from $0.19 previously. R&D expenses decreased 24.64% to $2.1 million, while G&A costs rose 8.7% to $2.5 million. Cash reserves fell to $13.1 million. The FDA cleared the IND for rexaceract, allowing Phase 2 trials to start in Q3 2026, with final Phase 1b results expected in Q4.
- Gain Therapeutics posted a Q2 net loss of USD 4.68 million, or USD 0.11 per share, narrowing from USD 0.19 per share a year earlier. * R&D expense fell 21.78% to USD 2.1 million, while G&A expense rose 8.7% to USD 2.5 million. * Cash and cash equivalents totaled USD 13.1 million at June 30, down from USD 20.8 million at Dec. 31. * FDA completed its review of the IND for rexaceract, clearing the way for a Phase 2 start in Q3 2026; final Phase 1b results are expected in Q4. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gain Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807509) on August 11, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)